N-[3-(benzylmethylamino)propyl]-3-dimethylaminobenzamide,
N-[3-(benzylmethylamino)propyl]-4-cyanobenzamide,
N-[3-(benzylmethylamino)propyl]-4-nitrobenzamide,
N-(2-(benzyl(methyl)amino)ethyl)-3-chlorobenzamide,
N-(2-(benzyl(methyl)amino)ethyl)-2,4-dichlorobenzamide,
N-(2-(benzyl(methyl)amino)ethyl)-4-cyanobenzamide,
N-(2-(benzyl(methyl)amino)ethyl)-4-nitrobenzamide,
N-[3-(benzylmethylamino)propyl]-4-chlorobenzensulfonamide,
4-(benzylmethylamino)-*N*-(4-chlorophenyl)butanamide,
N-(4-chlorobenzyl)-3-(benzylmethylamino)propanamide,
N-(4-nitrobenzyl)-3-(benzylmethylamino)propanamide,
N-(4-cyanobenzyl)-3-(benzylmethylamino)propanamide,
N-(2,4-dichlorobenzyl)-3-(benzylmethylamino)propanamide,
N-(3-chlorobenzyl)-3-(benzylmethylamino)propanamide, and
N-(4-chlorobenzyl)-3-(benzylmethylamino)propanamine.

11. A pharmaceutical composition comprising a compound according to any one of the preceeding claims or a pharmaceutically acceptable salt or solvate thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.

12. A compound according to any of Claims 1 to 10 or a pharmaceutically acceptable salt or solvate thereof for use as a medicament.

13. Use of a~~A~~ compound according to any of Claims 1 to 10 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for ~~use in~~ treating and/or preventing a sigma-1 receptor related disease.

14. The ~~compound for~~ use according to Claim 13, wherein the sigma-1 receptor related disease is a neurodegenerative disease.

15. The ~~compound for~~ use according to claim 14, wherein the neurodegenerative disease is selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic lateral sclerosis.

16. Use of a ~~A~~ compound according to any of Claims 1 to 10 or a

pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for ~~use in~~ the diagnosis of a sigma-1 receptor related disease.

17. Diagnostic imaging composition comprising a compound according to any of Claims 1 to 10 or a pharmaceutically acceptable salt or solvate thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.

~~18. Use of a compound according to any of Claims 1 to 10 or a pharmaceutically acceptable salt or solvate thereof as a modulator of sigma-1 receptor activity.~~